Research Topics
Species | C L LoprinziSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and painDeirdre R Pachman
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 30:3687-96. 2012..This article will focus on the management of these symptoms, including an assessment of the current research and proposed best- management practices...
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in miceLauren E Ta
Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
Mol Pain 6:15. 2010..The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation and nerve injury induced pain...
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trialCharles L Loprinzi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
Cancer 104:176-82. 2005..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product...
Phase III evaluation of fluoxetine for treatment of hot flashesCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:1578-83. 2002..Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed...
Tamoxifen-induced hot flashesC L Loprinzi
Mayo Clinic, Mayo Foundation, Rochester, MN, USA
Clin Breast Cancer 1:52-6. 2000....
Management of hot flashes in breast-cancer survivorsC L Loprinzi
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Lancet Oncol 2:199-204. 2001..Several studies in progress may provide better non-hormonal means of treating hot flashes in the future...
Pilot evaluation of gabapentin for treating hot flashesL Loprinzi
Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1159-63. 2002..To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes...
Newer antidepressants for hot flashes--should their efficacy still be up for debate?Charles L Loprinzi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Menopause 16:184-7. 2009..These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes...
Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experienceCharles L Loprinzi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Menopause 15:655-60. 2008..This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group...
The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanismCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
Cancer J 13:399-403. 2007..Herein, we characterize the clinical characteristics of this syndrome using detailed patient interviews and consider the putative mechanism(s) for these symptoms...
Doc, shouldn't we be getting some tests?Charles L Loprinzi
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:108s-111s. 2003
Why not start with thalidomide?Charles Loprinzi
Division of Medical Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
J Clin Oncol 21:2211-4. 2003
Symptom control trials: a 20-year experienceCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Support Oncol 5:119-25, 128. 2007....
Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5Charles L Loprinzi
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 25:308-12. 2007..No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone...
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7Charles L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 24:1409-14. 2006..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
The questions of prognosisCharles Loprinzi
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Support Oncol 3:340-1. 2005
Pilot evaluation of paroxetine for treating hot flashes in menCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 79:1247-51. 2004..To provide prospective information on the potential utility of paroxetine for treating hot flashes In men receiving androgen ablation therapy for prostate cancer...
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)C L Loprinzi
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Ann Oncol 20:542-9. 2009..Hot flashes represent a significant problem in men undergoing androgen deprivation therapy...
Newer antidepressants and gabapentin for hot flashes: a discussion of trial durationCharles L Loprinzi
Mayo Clinic, Rochester, MN, USA
Menopause 16:883-7. 2009..This article is devoted to providing scientific data to better ascertain how long it is necessary to conduct hot flash trials with newer centrally acting agents...
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysisCharles L Loprinzi
Division of Medical Oncology, Mayo Clinic, 200 First St Southwest, Rochester MN 55905, USA
J Clin Oncol 27:2831-7. 2009..This current project was developed to conduct an individual patient pooled analysis of the data from these published clinical trials...
Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapyC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 15:1235-8. 1997..Pursuant to preliminary data that suggested a sucralfate oral solution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test this contention...
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trialC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Lancet 356:2059-63. 2000..We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer...
Understanding the utility of adjuvant systemic therapy for primary breast cancerC L Loprinzi
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 19:972-9. 2001..To date, there has not been any widely available method for estimating the benefits from adjuvant systemic therapy, in terms of long-term disease-free survival probabilities, in patients with primary breast cancer...
Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1Charles L Loprinzi
Mayo Clinic Rochester, Rochester, MN 55905, USA
J Clin Oncol 28:641-7. 2010..Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes...
Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancerC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 15:969-73. 1997..The present trial was developed to evaluate the nonhormonal vaginal lubricating preparation, Replens, for alleviating these symptoms...
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1Charles L Loprinzi
Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
J Clin Oncol 29:1472-8. 2011..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...
Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physiciansCharles L Loprinzi
Mayo Clinic, Rochester, Minnesota 550905, USA
J Natl Compr Canc Netw 1:189-96. 2003..Two computer-based tools (Numeracy and Adjuvant!) are available to facilitate this process...
A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CACharles L Loprinzi
Mayo Clinic Rochester, Rochester, Minnesota, USA
J Support Oncol 9:105-12. 2011..This finding was confirmed by other secondary analyses. Toxicity evaluation revealed more nausea, sweating, rigors, and urinary frequency with the pilocarpine arms compared with the placebo arm...
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivorsC L Loprinzi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 16:2377-81. 1998..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexiaC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 17:3299-306. 1999..The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia...
Treatment of hot flushes in breast and prostate cancerKerin B Adelson
Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Expert Opin Pharmacother 6:1095-106. 2005..The most promising agents act on the CNS and include selective serotonin reuptake inhibitors, as well as venlafaxine and gabapentin...
Lack of effect of coumarin in women with lymphedema after treatment for breast cancerC L Loprinzi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
N Engl J Med 340:346-50. 1999..Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings...
Methodologic lessons learned from hot flash studiesJ A Sloan
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 19:4280-90. 2001..CONCLUSION: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity...
A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain indexJ A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 19:3539-46. 2001..The objective was to produce a simple, practical, stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease...
Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CBAmanda R Moraska
Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
J Support Oncol 8:128-32. 2010..These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572)..
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancerJ N Ingle
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Clin Cancer Res 5:1642-9. 1999..Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus letrozole was less than expected...
Sex differences in fluorouracil-induced stomatitisJ A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 18:412-20. 2000....
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathyJulie E Hammack
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Pain 98:195-203. 2002..Cross-validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy-related neuropathy...
Symptom management in premenopausal patients with breast cancerCharles L Loprinzi
Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Lancet Oncol 9:993-1001. 2008..Although some effective treatments can counteract symptoms related to cancer or treatments, research is needed to expand evidence-based care in premenopausal survivors of breast cancer...
Newer antidepressants and other nonhormonal agents for the treatment of hot flashesDomingo G Perez
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Compr Ther 31:224-36. 2005..This article reviews the clinical development of nonhormonal agents as alternatives to hormonal therapy for the management of hot flashes...
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1Barbara A Pockaj
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 24:2836-41. 2006..CONCLUSION: This trial failed to provide any evidence that black cohosh reduced hot flashes more than the placebo...
Pilot evaluation of citalopram for the relief of hot flashesDebra L Barton
Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 1:47-51. 2003..This pilot trial suggests that citalopram may be an effective non-hormonal treatment for hot flashes in women who can tolerate it...
Levetiracetam for the treatment of hot flashes: a phase II studySusan Thompson
Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
Support Care Cancer 16:75-82. 2008..The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors...
Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigationA Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Cancer 92:629-33. 2001..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancerD T Ransom
Mayo Clinic, Rochester, Minnesota 55905
Am J Clin Oncol 14:45-8. 1991..01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22%) and nine partial responses (39%), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months...
Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapyH J Long
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905
Am J Clin Oncol 11:524-7. 1988..Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin...
Coprescription of tamoxifen and medications that inhibit CYP2D6Kostandinos Sideras
Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
J Clin Oncol 28:2768-76. 2010....
Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomasStephan D Thome
Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:913-7. 2002....
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill
Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 22:1797-806. 2004....
Pilot evaluation of bupropion for the treatment of hot flashesDomingo G Perez
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Palliat Med 9:631-7. 2006..These data suggest that bupropion should not be further investigated as a remedy for hot flashes...
Pilot evaluation of mirtazapine for the treatment of hot flashesDomingo G Perez
Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 2:50-6. 2004....
Current management of cancer-associated anorexia and weight lossA Jatoi
Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
Oncology (Williston Park) 15:497-502, 508; discussion 508-10. 2001....
Chemotherapy-induced peripheral neuropathy: prevention and treatmentD R Pachman
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Clin Pharmacol Ther 90:377-87. 2011..Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury...
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CCStephanie L Hines
Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
Breast Cancer Res Treat 117:603-9. 2009..Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen...
A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patientsAminah Jatoi
Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Support Care Cancer 12:859-63. 2004..The safety and pharmacokinetics of infliximab in combination with docetaxel, a commonly used chemotherapy agent for non-small-cell lung cancer, were explored in this pilot study...
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment GroupAminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 110:1396-403. 2007....
Pilot evaluation of flaxseed for the management of hot flashesSandhya Pruthi
Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Soc Integr Oncol 5:106-12. 2007..This study suggests that dietary therapy decreases hot flash activity in women not taking estrogen therapy. This reduction is greater than what would be expected with placebo...
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancerStephanie L Hines
Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 27:1047-53. 2009..Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer...
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)Aminah Jatoi
Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Lung Cancer 68:234-9. 2010....
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancerRobert S Sandler
Department of Medicine, University of North Carolina, Chapel Hill 27599 7555, USA
N Engl J Med 348:883-90. 2003..Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers...
Physical activity in patients with advanced-stage cancer actively receiving chemotherapyMatthew M Clark
Department of Psychiatry and Psychology, Cancer Treatment Unit, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Support Oncol 5:487-93. 2007..Future research will investigate how these findings may be incorporated into physical activity interventions for advanced-stage oncology patients receiving medical treatment...
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8Ann E Kearns
Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 18:321-8. 2010..The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer...
High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assayHongzhi Zou
Miles and Shirley Fiterman Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 136:459-70. 2009..We developed a digital melt curve (DMC) assay to quantify low-abundance mutations in stool samples for detection of colorectal neoplasms and compared this test with other approaches...
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3Ravi D Rao
Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 112:2802-8. 2008..Based on such data, a multicenter double-blind, placebo-controlled, randomized trial was conducted to evaluate the effect of lamotrigine on pain and other neuropathic symptoms due to chemotherapy-induced peripheral neuropathy (CIPN)...
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group studyAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:567-73. 2002..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)Aminah Jatoi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 113:847-53. 2008..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigationAminah Jatoi
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Support Care Cancer 10:71-5. 2002..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
Pathophysiology and treatment of hot flashesTait D Shanafelt
Department of Oncology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1207-18. 2002..The use of clonidine, methyldopa, and belladonna should be discouraged because of their modest efficacy and adverse effects...
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CADebra L Barton
Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 18:179-87. 2010..This pilot trial sought to investigate whether any of three doses of American ginseng (Panax quinquefolius) might help cancer-related fatigue. A secondary aim was to evaluate toxicity...
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyStephanie L Hines
Mayo Clinic Florida, Jacksonville, FL 32224, USA
Breast 19:92-6. 2010..Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole...
Chemotherapy-induced ovarian failure: manifestations and managementJulian R Molina
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Drug Saf 28:401-16. 2005....
The prevalence of weight concerns in a smoking abstinence clinical trialMatthew M Clark
Mayo Clinic Mayo Building W11, 200 First Street, SW, Rochester, MN 55905, USA
Addict Behav 31:1144-52. 2006..Additionally, being weight concerned may impact the short-term success rates of stopping smoking using pharmacotherapy...
North Central Cancer Treatment Group--achievements and perspectivesAxel Grothey
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Semin Oncol 35:530-44. 2008....
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxineCharles L Loprinzi
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Palliat Med 8:924-30. 2005....
The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)Debra L Barton
Mayo Clinic Rochester, Rochester, MN 55905, USA
J Support Oncol 9:24-31. 2011..However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted...
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252Edith A Perez
Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
Clin Breast Cancer 6:425-32. 2005..The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial...
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effortAminah Jatoi
Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Oncol 22:2469-76. 2004..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)Aminah Jatoi
Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
Oncologist 15:1016-22. 2010..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9Debra L Barton
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 28:3278-83. 2010..Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief...
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CADebra L Barton
Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 19:833-41. 2011..The purpose of this double-blind randomized placebo-controlled trial was to evaluate a novel compounded topical gel for this problem...
Making sense of the evidence regarding nonhormonal treatments for hot flashesDebra Barton
Clin J Oncol Nurs 8:39-42. 2004..This algorithm includes nonhormonal options of the antidepressants available in addition to gabapentin, an antiseizure medication. A short review of the evidence for possible complementary therapies also is included...
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trialSteven R Alberts
Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Am J Ther 13:291-7. 2006..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
Centrally active nonhormonal hot flash therapiesCharles L Loprinzi
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Med 118:118-23. 2005..The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing...
Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse preventionIvana T Croghan
Nicotine Research Center, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:186-95. 2007..To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention...
A critical review of complementary therapies for cancer-related fatigueAmit Sood
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Integr Cancer Ther 6:8-13. 2007..To review the available literature on the use of complementary and alternative medicine (CAM) treatments for cancer-related fatigue with an aim to develop directions for future research...
Pilot evaluation of black cohosh for the treatment of hot flashes in womenBarbara A Pockaj
Department of Surgery, Mayo Clinic, Scottsdale, Arizona 85259, USA
Cancer Invest 22:515-21. 2004..Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes...
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4Robert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 79:1460-6. 2011..A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy...
Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trialAminah Jatoi
Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 12:640-4. 2004..As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome...
Stool DNA and occult blood testing for screen detection of colorectal neoplasiaDavid A Ahlquist
Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Intern Med 149:441-50, W81. 2008..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancerJeff A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 20:1491-8. 2002..After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken...
Palliative communications: addressing chemotherapy in patients with advanced cancerK C Kadakia
Division of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Ann Oncol 23:29-32. 2012..Compassionate and honest communication about the use of chemotherapy can facilitate better patient care. This manuscript will explore communication issues regarding palliative-intent chemotherapy...
An update: cancer-associated anorexia as a treatment targetA Jatoi
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Curr Opin Clin Nutr Metab Care 4:179-82. 2001..To date, however, palliative options remain limited. Megestrol acetate and dexamethasone provide only modest relief. Novel agents such as thalidomide, adenosine triphosphate, and other cytokine inhibitors merit further investigation...
Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicityC L Loprinzi
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905
Cancer Invest 8:459-65. 1990..There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops...
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5Sherry L Wolf
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 28:5182-7. 2010..This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS...
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7Axel Grothey
Mayo Clinic Rochester, Rochester, MN 55905, USA
J Clin Oncol 29:421-7. 2011..In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT...
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancerDavid P Steensma
Mayo Clinic and Mayo Foundation, Rochester 55905, USA
J Clin Oncol 24:1079-89. 2006..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia...
Stellate-ganglion block: a new treatment for hot flushes?Charles L Loprinzi
Lancet Oncol 9:506-7. 2008
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guidelineChristopher E Desch
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 23:8512-9. 2005..Chest x-rays, CBCs, and liver function tests are not recommended, and molecular or cellular markers should not influence the surveillance strategy based on available evidence...
Erythropoietin use in cancer patients: a matter of life and death?David P Steensma
J Clin Oncol 23:5865-8. 2005
Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasStacy D Jacobson
Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Support Oncol 1:274-8. 2003..96). Thus this trial did not suggest any role for oral glutamine, compared with placebo, for preventing the development, or alleviating the severity, of paclitaxel-induced myalgias/arthralgias...
Epoetin alfa and darbepoetin alfa go head to headDavid P Steensma
J Clin Oncol 24:2233-6. 2006
Research Grants
- COMMUNITY CLINICAL ONCOLOGY PROGRAMCharles Loprinzi; Fiscal Year: 2006..abstract_text> ..
- CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITYCharles Loprinzi; Fiscal Year: 2003..abstract_text> ..
- CAPITATIONCharles Loprinzi; Fiscal Year: 2007..Funding is requested for this submission to support 375 total accruals at all non-CCOP NCCTG sites at the current rate of $2,000 each, for a total request of $750,000. ..
